

Sheet 1 of 5

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/114001
		Serial No.	10/595,161
		Applicant	Waer et al.
		Filing Date	March 10, 2006
		Group	2621
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		IDS Filed	May 16, 2007
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication/ Issue Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
arb	2003/236255	12-25-2003	Waer et al.			
arb	2,512,572	06-20-1950	Smith, Jr. et al.			
arb	2,581,889	01-08-1952	Timmis			
arb	2,665,275	01-05-1954	Campbell et al.			
arb	2,667,486	01-26-1954	Cain			
arb	2,740,784	04-03-1956	Sletzing et al.			
arb	2,940,972	06-14-1960	Roch			
arb	3,071,587	01-01-1963	Curran			
arb	3,081,230	03-12-1963	Weinstock et al.			
arb	3,159,628	12-01-1964	Pachter et al.			
arb	3,475,425	10-1969	Roch, Joseph			
arb	3,859,287	01-07-1975	Parish et al.			
arb	5,665,772	09-09-1997	Cottens et al.			
arb	5,780,462	07-14-1998	Lee et al.			
arb	5,843,943	12-1-1998	Carson et al.			
arb	5,992,713	11-30-1999	Manabat			
arb	6,331,547	12-18-2001	Zhu et al.			
arb	6,440,991	08-27-2002	Zhu et al.			
arb	2006/0189620	8-24-2006	Waer et al.			
pu	2007/0043000	2-22-2007	Waer et al.			

EXAMINER <i>Regina Hughes</i>	DATE CONSIDERED <i>2/1/2008</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/114001
	Serial No.	10/595,161
	Applicant	Waer et al.
	Filing Date	March 10, 2006
	Group	2621
	IDS Filed	May 16, 2007

U.S. PATENT DOCUMENTS						
<i>arb</i>	2006/0287314	12-21-2006	Waer et al.			
<i>arb</i>	2007/0032477	02-08-2007	Waer et al.			
<i>arb</i>	6,946,465	09-20-2005	Waer et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication or Issue Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
<i>arb</i>	CH 231,852	07-17-1944	Switzerland			
<i>arb</i>	DE 19 21 308	01-07-1971	Germany			
<i>arb</i>	DE 40 09 941	10-02-1991	Germany			
<i>arb</i>	EP 0 108 890	05-23-1984	EPO			
<i>arb</i>	EP 0 134 922	03-27-1985	EPO			
<i>arb</i>	EP 0 185 259	06-25-1986	EPO			
<i>arb</i>	EP 0 956 855	11-17-1999	EPO			
<i>arb</i>	EP 1 479 682	11-24-2004	EPO			
<i>arb</i>	EP 0 574 906	12-22-1993	EPO			
<i>arb</i>	GB 2 405 793	03-16-2005	United Kingdom			
<i>arb</i>	GB 677,342	08-13-1952	United Kingdom			
<i>arb</i>	GB 763,044	12-05-1956	United Kingdom			
<i>arb</i>	GB 785,353	10-30-1957	United Kingdom			
<i>arb</i>	WO 00/45800	08-10-2000	WIPO			
<i>arb</i>	WO 01/19825	03-22-2001	WIPO			

EXAMINER <i>Michael Hughes</i>	DATE CONSIDERED <i>2/11/2008</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/114001
	Serial No.	10/595,161
	Applicant	Waer et al.
	Filing Date	March 10, 2006
	Group	2621
	IDS Filed	May 16, 2007

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
art	WO 94/11001	05-26-1994	WIPO			
art	WO 94/06431	03-31-1994	WIPO			
art	WO 95/31987	11-30-1995	WIPO			
art	WO 95/32203	11-30-1995	WIPO			
art	WO 98/04558	02-5-1998	WIPO			
art	WO 98/08516	03-5-1998	WIPO			
art	WO 98/52948	11-26-1998	WIPO			
art	WO 04/104005	12-02-2004	WIPO			
art	WO 05/021003	03-10-2005	WIPO			
art	WO 05/039587	05-06-2005	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
art	Baba et al., "Synergistic Antiviral Effects of Antiherpes Compounds and Human Leukocyte Interferon on Varicella-Zoster Virus in Vitro," <i>Antimicrob. Agents Chemother.</i> 25:515-517 (1984).
art	Beilstein search, XP-002324247.
art	Beilstein Database, <i>Beilstein Institute For Organic Chemistry</i> 28:1015-1020 (1992), XP-002296933.
art	Beilstein Database, <i>Beilstein Institute For Organic Chemistry</i> 90:2631, 2633, 2635 (1957) XP-002296934.
art	Beilstein Database, <i>Beilstein Institute For Organic Chemistry</i> 93:2668, 2671 (1960) XP-002296935.
art	Beilstein Database, <i>Beilstein Institute For Organic Chemistry</i> 52:1403-1410 (2003) XP-002296936.
art	Beilstein Database, <i>Beilstein Institute For Organic Chemistry</i> 41:781-788 (1995) XP-002296937.
art	Beilstein Database, <i>Beilstein Institute For Organic Chemistry</i> 48:1255-1274 (1998) XP-002296938.
art	Black et al., "Agents that Block TNF- α Synthesis or Activity," <i>Ann Rep. Med. Chem.</i> 32:241-250 (1997).
art	Boon, "Pteridines. Part IV.* Derivatives of 2:4-Diaminopteridine and Related Compounds," <i>J. Chem. Soc.</i> 2146-2158 (1957).

EXAMINER	<i>Michael Hughes</i>	DATE CONSIDERED	2/1/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/114001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/595,161
		Applicant	Waer et al.
		Filing Date	March 10, 2006
		Group	2621
		IDS Filed	May 16, 2007
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

<i>arb</i>	Cairo, "Immunology Lecture #20 Transplantation Immunology," <i>Columbia University</i> , [online] (2003).
<i>arb</i>	Chantry "Emerging Drugs: The Prospect for Improved Medicines," 1:5-13 (1999).
<i>arb</i>	Chou and Talalay, "Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors," <i>Adv. Enzyme Regul.</i> 22:27-55 (1984).
<i>arb</i>	Cottam et al., "Substituted Xanthines, Pteridinediones and Related Compounds as Potential Anti-Inflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor alpha.," <i>J. Med. Chem.</i> 39:2-9 (1996).
<i>arb</i>	Elion et al., "Antagonists of Nucleic Acid Derivatives. VIII. Synergism in Combinations of Biochemically Related Antimetabolites," <i>J. Biol. Chem.</i> 208:477-488 (1954).
<i>arb</i>	Elliott et al., "Synthesis of N-10-Methyl-4-Thiofolate Acid and Related Compounds," <i>Journal of Medicinal Chemistry</i> 18:492-496 (1975).
<i>arb</i>	Giori et al., "Reactivity of 3H-Pyrimido[5, 4-c] [1, 2, 5] Oxadiazin-3-one Towards Carbanions: Synthesis of Pteridine-2, 4-Diones," <i>J. Heterocyclic Chemistry</i> 23:1661-1665 (1986).
<i>arb</i>	Illei and Lipsky, "Novel, non-Antigen-Specific Therapeutic Approaches to Autoimmune/Inflammatory Diseases," <i>Current Opinion in Immunology</i> 12:712-718 (2000).
<i>arb</i>	Israel et al., "Pyrimidine Derivatives. VII. Some Condensed Derivatives of 2, 4, 5-Triamino-6-Methylthiopyrimidine," <i>Journal of Pharmaceutical Sciences</i> 54:1626-1632 1965.
<i>arb</i>	Kaldrikyan, M.A. et al., "Pteridine Derivatives. I. Synthesis of Some Substituted 6,7-Diarylpteridines," <i>Armianskii Khimicheskii Zhurnal</i> 29:337-341 (1976) (abstract only)
<i>arb</i>	Landauer and Rydon, "A Convenient Synthesis of Some 4-Substituted 5-Aminopyrimidines," <i>J. Chem. Soc.</i> 3721-3722 (1953).
<i>arb</i>	Lin et al., "Use of the Methylxanthine Derivative A802715 in Transplantation Immunology, I. Strong in Vitro Inhibitory Effects on CD28-Costimulated T Cell Activities," <i>Transplantation</i> 63:1813-1819 (1997).
<i>arb</i>	Lin et al., "Use of the Methylxanthine Derivative A802715 in Transplantation Immunology, II. In Vivo Experiments," <i>Transplantation</i> 63:1734-1738 (1997).
<i>arb</i>	Merz et al., "Synthesis of 7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and Novel Derivatives Free of Positional Isomers. Potent Inhibitors of cAMP-Specific Phosphodiesterase and of Malignant Tumor Cell Growth," <i>J. Med. Chem.</i> 41:4733-4743 (1998).
<i>arb</i>	Mohr et al., "Pteridines: Synthesis and Properties of 6-Thioxanthopterin and 7-Thioisoxanthopterin," <i>Helv. Chim. Acta</i> 75:2317-2326 (1992).


EXAMINER <i>Shirley Hughes</i>	DATE CONSIDERED <i>8/11/2008</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/114001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/595,161
		Applicant	Waer et al.
		Filing Date	March 10, 2006
		Group	2621
		IDS Filed	May 16, 2007
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

arb	Murata et al., "A Facile Method for Regioselective 6,7-Disubstitution of Pteridine," <i>Heterocycles</i> 53:1259-1262 (2000).
arb	Pfleiderer and Lohrmann, "Pteridine, XII: Synthese von 2-Amino-4-Alkoxy-Pteridinen," <i>Chem. Ber.</i> 94:12-18 (1961).
arb	Sato and Fukuya, "Studies on Pyrazines. Part 37. 'Synthesis of 6-Propionylpteridine-2,4 (1 <i>H</i> ,3 <i>H</i>)-dione and its 1-and/or 3-Methyl Derivatives from Marine Natural Products," <i>J. Chem. Soc., Perkin Trans.</i> 1:89-95 (2000).
arb	Spickett et al., "The Synthesis of Compounds With Potential Anti-Folic Acid Activity. Part I. 7-Amino- And 7-Hydroxy-Pteridines," <i>Journal of The chemical Society, Chemical Society. Letchworth</i> 2887-2891 (1954).
arb	Weinstock et al., "Pteridines. XII. Structure-Activity Relationships of Some Pteridine Diuretics," <i>J. Med. Chem.</i> 11:573-579 (1968).
arb	West, "Chapter 10 Solid Solutions: Solid State Chemistry and its Applications," <i>Wiley</i> 358 & 365 (1988).
arb	Yao and Pfeleiderer, "Pteridines. Protection of Pteridines", <i>Helvetica Chimica Acta</i> , 86:1-12 (2003).
arb	Neilsen et al., "Unequivocal syntheses of 6-methyl- and 6-phenylisoxanthopterin" <i>J. Heterocyclic Chem.</i> , 24, 1621-1628 (1987)
arb	Taghavi-Moghadam et al., "A new, general, and regioselective method for the synthesis of 2, 6-disubstituted 4-aminopteridines", <i>Tetrahedron Lett.</i> , 38 (39), 6835-6836 (1997)
arb	Jackson et al., "6, 7-disubstituted 2, 4-diaminopteridines: novel inhibitors of <i>Pneumocystis carinii</i> and <i>Toxoplasma gondii</i> dihydrofolate reductase", <i>Antimicrobial Agents and Chemotherapy</i> , 40:1371-1375 (1996)
arb	Magnus et al. "Neural stem cells in inflammatory CNS diseases: mechanisms and therapy" <i>J. Cell. Mol. Med.</i> 2005, 9:303-319.
arb	Obach "Drug-drug interactions: an important negative attribute in drugs" <i>Drugs of Today</i> 2003, 39:301-338.
arb	Cecil Textbook of Medicine, 20 th edition (1996), Section Five- Degenerative Diseases of the Nervous System, vol. 2, pp:2050-2057.
arb	Cecil Textbook of Medicine, 20 th edition (1996), vol. 2, pp:1992-1996.
arb	"FDA mulls drug to slow late-stage Alzheimer's" <i>cnn.com</i> 9/24/2003.
arb	Wikipedia entries for Antihistamine, Autoimmunity, List of autoimmune diseases, Lupus erythematosus, and Sjogren's syndrome, printed from http://en.wikipedia.org on December 28, 2006.

EXAMINER <i>J. C. H. H. H.</i>	DATE CONSIDERED <i>2/11/2008</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/114001
	Serial No.	10/595,161
	Applicant	WAER et al.
	Filing Date	March 10, 2006
	Group	Not yet assigned
	IDS Filed	May 26, 2006
	Customer No.	21559

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
arl	3,122,546	02/25/64	Osdene			
arl	5,047,405	09/10/91	Gennari			
arl	5,300,509	04/05/94	Block et al.			
arl	5,500,428	03/19/96	Block et al.			
arl	5,929,046	07/27/99	McMurry et al.			
arl	6,043,228	03/28/00	McMurry et al.			
arl	2004/077859A1	04/22/04	Albert Waer et al.			
arl	2004/102447 A1	05/27/04	Bonnert et al.			
arl	6,844,343B1	01/18/05	Pfleiderer et al.			
arl	2005/054653A1	03/10/05	Eisenbrand et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
arl	DD 267 495 A1	05/03/89	Germany			No
arl	EP 0 290 819	04/18/88	EPO			
arl	EP 0 362 645	09/23/89	EPO			
arl	EP 0 544 445	11/19/92	EPO			
arl	WO 00/39129	07/06/00	WIPO			
arl	WO 01/21619	03/29/01	WIPO			Abstract Only
arl	WO 02/32507	04/25/02	WIPO			
arl	WO 03/062240	07/31/03	WIPO			Abstract Only

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 2/1/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/114001
		Serial No.	10/595,161
		Applicant	WAER et al.
		Filing Date	March 10, 2006
		Group	Not yet assigned
		IDS Filed	May 26, 2006
		Customer No.	21559

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
<i>al</i>	Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories: Whitehouse Station, N.J., <i>Leukemias</i> , Chapt. 138:953-954 (1999).
<i>al</i>	Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories: Whitehouse Station, N.J., <i>Neurologic Disorders</i> , Sec. 14:1474-1476 (1999).
<i>al</i>	Fröhlich et al., "Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives: Structure-Activity Relationship of Antagonists of (6R)-5,6,7,8-Tetrahydrobiopterin Cofactor," <i>J. Med. Chem.</i> 42:4108-4121 (1999).
	Landry and Gies, <i>Pharmacologie. Des Cibles Vers L'Indication Thérapeutique: Cours et Exercices</i> , Dunod: Paris, p.177 (2003).
<i>al</i>	Matter et al., "Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I): 3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors," <i>J. Med. Chem.</i> 45:2923-2941 (2002).
<i>al</i>	Moreb and Zucali, "The Therapeutic Potential of Interleukin-1 and Tumor Necrosis Factor on Hematopoietic Stem Cells," <i>Leuk. Lymphoma</i> 8:267-275 (1992) (Abstract Only).
<i>al</i>	Nicolaus, "Symbiotic Approach to Drug Design," in Decision Making in Drug Research, Gross (ed.), Raven Press: New York, p.173-186 (1983).
<i>al</i>	PCT International Search Report (PCT/EP2004/010198) (mailed 26 April 2005).
<i>al</i>	PCT Written Opinion of the International Preliminary Examining Authority (PCT/EP2004/010198) (mailed 01 September 2005).
<i>al</i>	PCT Written Opinion of the International Searching Authority (PCT/EP2004/010198).
<i>al</i>	Response to the Written Opinion (PCT/EP2004/010198) (mailed 28 October 2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	